In-article:

Equasens: Notice of meeting of the Extraordinary General Meeting







Villers-lès-Nancy, September 11, 2020 – 6:00 p.m. (CET)

PRESS RELEASE

CONVENING OF THE EXTRAORDINARY GENERAL MEETING

FROM SEPTEMBER 25, 2020

The Extraordinary General Meeting of PHARMAGEST INTERACTIVE is convened for Friday September 25, 2020 at 5:30 p.m., at the Company’s Head Office – 5 Allée de Saint Cloud in Villers-lès-Nancy.

In the context of the COVID-19 epidemic,this Extraordinary General Meeting will exceptionally be held behind closed doors.

The prior notice of the meeting was published in the Bulletin des Annonces Légales Obligatoires (BALO) of August 19, 2020. The notice of meeting was published on September 9, 2020 in the BALO as well as in the legal announcements journal Les Tablettes Lorraines.

The agenda, the draft resolutions proposed to the vote of the shareholders by the Board of Directors as well as the description of the main methods of participation and voting at the Meeting and the exercise of the rights of the shareholders, have been published in each of these reviews.

These notices to the BALO are also available on the Company’s website: www.pharmagest.com– FINANCE section – General Meeting tab.

Special methods of organization and participation

In the context of the COVID-19 epidemic and the fight against its spread, the methods of organization and participation of shareholders in the Extraordinary General Meeting have been adapted.

In accordance with Article 4 of Ordinance No. 2020-321 of March 25, 2020 taken on the basis of Emergency Law No. 2020-290 of March 23, 2020 to deal with the prolonged COVID-19 epidemic until November 30, 2020 by Decree No. 2020-925 of July 29, 2020 extending the period of application of Ordinance No. 2020-321 of March 25, 2020, Decree No. 2020-418 of April 10, 2020 and of Decree No. 2020-629 of May 25, 2020, the Extraordinary General Meeting of September 25, 2020 will be held, by decision of the Board of Directors, without the shareholders and other persons entitled to attend being present physically or by telephone or audiovisual conference.

Shareholders may vote either by post or by proxy. These means of participation made available to shareholders are now the only possible ones.

Shareholders are invited to consult the section dedicated to the 2020 General Meeting on the Company’s website: www.pharmagest.com– FINANCE section – General Meeting tab.

Methods of informing shareholders

In accordance with Article R. 225-73-1 of the French Commercial Code, the documents or information relating to the General Meeting as well as the forms for voting by correspondence or by proxy are posted on the Company’s website: www.pharmagest.com– FINANCE section – General Meeting tab, since September 4, 2020.

Shareholders may request communication of documents that are not accessible online by sending a request by e-mail to the following address: [email protected]. LSince delivery times for mail are uncertain, the Company strongly invites shareholders to give priority to sending all their requests and documents electronically.

Press release September 11, 2020 –

Notice of meeting of the Extraordinary General Meeting – 2

About Pharmagest Group:

The Pharmagest Group is the French leader in health IT with more than 44% market share in dispensing pharmacy IT, 28% of EHPADs, 45% of HADs, 20% of nursing homes. With more than 1,000 employees, the Pharmagest Group’s strategy revolves around a core business: IT innovation at the service of Health and the development of 2 priority areas: 1/ services and technologies for healthcare professionals health ; 2/ the technological fields capable of improving the efficiency of health systems.

To serve this strategy, the Pharmagest Group has developed specialized businesses: pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for healthcare and medico-social establishments (for nursing homes, SSIAD, HAD, CLIC , MSP and Hospitals), solutions for pharmaceutical laboratories, applications and connected health objects, sales financing marketplace, etc.

These activities are divided into 4 Divisions: Pharmacy Solutions Europe, Solutions for Healthcare and Medico-Social Establishments, e-Health Solutions and Fintech.

Listed on Euronext Paris™ – Compartment B

Clues: CAC® SMALL and CAC® All-Tradable by inclusion

Eligible for the Deferred Settlement Service (SRD) Long-only

ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: – PMGI FP

PHARMAGEST shares are PEA-PME eligible.

The Group is included in the

  • European Rising Tech » who
    Brussels, Lisbon and Paris.

Gaia-INDEX2019the index of responsible mid-caps, and recently joined the label rewards the best performing technology SMEs on the Euronext markets in Amsterdam,

Disclaimer

Equasens SA published this content on September 26, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 September 2022 18:50:05 UTC.

Publicnow 2022

All the news on EQUASENS

Analyst recommendations on EQUASENS
09/23Opinion of analysts of the day: Veolia, Neoen, Valneva, Nexity, Bure..
ZB
08/04Opinion of analysts of the day: HSBC, JCDecaux, Elior, Equasens, Dia..
ZB
03/28Opinion of analysts of the day: Bouygues, Renault, Gecina, Dassault..
ZB

2022 turnover 215M
207M
2022 net result 45.3M
43.7M
trso. net 2022 17.4M
16.8M
PER 202221.7x
2022 return1.99%
Capitalization 999M
964M
VE / CA 20224.57x
VE / CA 20234.02x
Number of employees
Floating32.1%


Hard :

Period:




Equasens: Chart technical analysis Equasens |  Market area

Trends technical analysis EQUASENS

Short termMiddle termLong term
Trendsbearishbearishbearish

Evolution of the Income Statement

Sale

Purchase

Average recommendationTO BUY
Number of Analysts3
Last Closing Price€66.60
Average price target€103.80
Deviation / Average Target55.9%

Officers and Directors

Var. Jan 1capi. ($M)
EQUASENS-26.28%1,011




Source link -88